Currax Pharmaceuticals LLC (Currax), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE (naltrexone HCl/bupropion HCl, today announced that the U.S. Food & Drug Administration (FDA) has approved a second manufacturing site for CONTRAVE, also marketed as MYSIMBA in the European Union and European Economic Area. This approval comes at a critical time as demand for effective obesity treatments surges worldwide and reinforces the company's commitment to continuous patient access to treatment.
"At Currax, we are steadfast in our commitment to ensuring that patients and healthcare providers have uninterrupted access to CONTRAVE," states Aaron Chesnut, Vice President Technical Operations. "Securing a second FDA-approved drug product manufacturing site enhances our ability to respond to shifting industry conditions and safeguards against external factors that could impact production and distribution."
The approval of this second site enhances production capacity, confirming continued patient access to CONTRAVE while reinforcing the company's broader commitment to obesity research and treatment. Currax is investing in manufacturing and advancing clinical research, and is working to provide reliable, evidence-based treatment options for patients and healthcare providers.
"As the obesity epidemic continues to rise, so does the need for dependable access to effective and affordable treatment options," said George Hampton, President and CEO of Currax Pharmaceuticals. "As the only medication in the Reward System Modulator (RSR) class, CONTRAVE is an important treatment option for physicians, particularly as the development programs continue to focus on the (GLP-1s)."
